AP NEWS

Dr. Reddy’s Laboratories Announces the Launch of Imatinib Mesylate Tablets, USP in the U.S. Market

October 1, 2018

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Oct 1, 2018--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec (imatinib mesylate) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA).

The Gleevec brand and generic had U.S. sales of approximately $868 million MAT for the most recent twelve months ending in July 2018 according to IMS Health*.

Dr. Reddy’s Imatinib Mesylate Tablets, USP is available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.

Gleevec is a trademark of Novartis Pharmaceuticals Corporation.

*IMS National Sales Perspective: Retail and Non-Retail MAT July 2018 RDY-0918-215

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180930005065/en/

CONTACT: Dr. Reddy’s Laboratories Ltd.

INVESTOR RELATIONS

SAUNAK SAVLA

Ph: +91-40-49002135

saunaks@drreddys.com

or

MEDIA RELATIONS

CALVIN PRINTER

Ph: +91-40-49002121

calvinprinter@drreddys.com

KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA NEW JERSEY INDIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL FDA

SOURCE: Dr. Reddy’s Laboratories Ltd.

Copyright Business Wire 2018.

PUB: 10/01/2018 01:45 AM/DISC: 10/01/2018 01:45 AM

http://www.businesswire.com/news/home/20180930005065/en

AP RADIO
Update hourly